Inidascamine

Last updated

Inidascamine
Inidascamine.svg
Clinical data
Other namesRL-007; RL007; FSV7-007
Routes of
administration 		Oral [1] [2]
Identifiers
  • (2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C12H17N3O2
Molar mass 235.287 g·mol−1
3D model (JSmol)
  • C1CCN(C1)C(=O)[C@@H]([C@H](C2=CC=NC=C2)O)N
  • InChI=1S/C12H17N3O2/c13-10(12(17)15-7-1-2-8-15)11(16)9-3-5-14-6-4-9/h3-6,10-11,16H,1-2,7-8,13H2/t10-,11+/m1/s1
  • Key:GRZMKKUGHIECFK-MNOVXSKESA-N

Inidascamine (INN Tooltip International Nonproprietary Name; developmental code names RL-007, FSV7-007) is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS). [1] [3] [4] [5] [6] [2] It is taken orally. [1] [2] The drug is said to act on the cholinergic, NMDA, and GABAB receptor systems. [1] [5] [2] Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences. [1] [3] It was discovered via screening of compounds for effects on synaptic plasticity and cognition. [2] The drug shows structural similarities to phenethylamines and amphetamines. [7]

See also

References

  1. 1 2 3 4 5 "RL 007". AdisInsight. 10 June 2024. Retrieved 26 February 2025.
  2. 1 2 3 4 5 Donello JE, Walker GA, Schweighoffer F, and Pando MP. Abstract Number: 149. RL-007, a novel oral neuromodulator, enhances synaptic plasticity and cognition in non-clinical models. American College of Neuropsychopharmacology (ACNP) annual meeting. December 5, 2023. https://ir.atai.life/static-files/06c60339-e93c-42fc-9323-c0e38e83f86e
  3. 1 2 "Delving into the Latest Updates on RL-007 with Synapse". Synapse. 23 January 2025. Retrieved 26 February 2025.
  4. ↑ Brady LS, Lisanby SH, Gordon JA (2023). "New directions in psychiatric drug development: promising therapeutics in the pipeline". Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555. PMID   37352473.
  5. 1 2 Vita A, Barlati S, Cavallaro R, Mucci A, Riva MA, Rocca P, et al. (2024). "Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations". Frontiers in Psychiatry. 15: 1451832. doi: 10.3389/fpsyt.2024.1451832 . PMC   11450451 . PMID   39371908.
  6. ↑ Ye N, Wang Q, Li Y, Zhen X (March 2025). "Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities". Medicinal Research Reviews. 45 (2): 755–787. doi:10.1002/med.22086. PMID   39300769.
  7. ↑ "2-Amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one, (2R,3S)-". PubChem. Retrieved 26 February 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.